July 01, 2022
1 min learn
In the course of the Worldwide Liver Congress, specialists supplied updates on the rising outbreak of acute, extreme hepatitis of unknown etiology in kids.
As of June 20, each new and retrospectively recognized instances have been reported in 33 international locations, based on Philippa Easterbrook, MD, senior scientist on the International HIV, Hepatitis and STI Packages at WHO headquarters in Geneva. It was the highest story in gastroenterology final week.
One other prime story was about remission charges amongst sufferers with Crohn’s illness who acquired remedy with ustekinumab or adalimumab, which researchers mentioned have been “surprisingly excessive.”
Learn these and extra prime tales in gastroenterology beneath:
Acute hepatitis outbreak swells to just about 900 instances; world knowledge reveals ‘combined image’
An outbreak of acute, extreme hepatitis of unknown etiology in kids has grown to 894 instances throughout 33 international locations, based on knowledge offered throughout a media briefing on the Worldwide Liver Congress. Read more.
‘Surprisingly excessive’ remission charges for each ustekinumab, adalimumab in Crohn’s sufferers
Ustekinumab and adalimumab demonstrated equally excessive charges of medical remission in biologic-naïve sufferers with reasonable to extreme Crohn’s illness by way of 1 yr of remedy, based on outcomes of the SEAVUE examine in The Lancet. Read more.
WHO: HCV elimination by 2030 calls for ‘scale-up, simplification’ of care pathways
WHO offered up to date steerage on hepatitis C, calling for drastic simplification of care pathways to alleviate entry gaps in HCV testing and remedy, throughout a joint WHO-EASL-CDC symposium on the Worldwide Liver Congress. Read more.
AGA proposes first pharmacologic remedy plan for sufferers with IBS-C, IBS-D
The American Gastroenterological Affiliation has issued medical tips that define a pharmacologic remedy plan for sufferers with irritable bowel syndrome and its subtypes, IBS-constipation and IBS-diarrhea. Read more.
Antiviral mixture plus normal remedy achieves ‘managed organic state’ in HBV
Remedy combining small interfering RNA, capsid meeting modulator and nucleotide analogue decreased HBsAg ranges over 24 weeks in contrast with normal remedy, based on a presenter on the Worldwide Liver Congress. Read more.